期刊
DIABETES & VASCULAR DISEASE RESEARCH
卷 9, 期 2, 页码 95-108出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164112441526
关键词
Cardiovascular disease; clinical perspective; GLP-1 receptor agonists; type 2 diabetes
资金
- Heart & Stroke Foundation of Ontario (HSFO) [T6757, CI6824]
- Amylin
- Merck Co
- NovoNordisk
- Roche
The active incretin hormone glucagon-like peptide-1 (7-36)amide (GLP-1) is a 30-amino acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an agonist for the GLP-1 receptor (GLP-1R). In addition to its anti-diabetic effects, GLP-1 has demonstrated cardioprotective actions. Here we review the cardiovascular effects of the GLP-1 analogues currently approved for the treatment of type 2 diabetes, namely exenatide and liraglutide. We discuss their anti-hyperglycaemic efficacy, and offer a clinical perspective of their effects on cardiovascular risk factors such as body weight, blood pressure, heart rate and lipid profiles, as well as their potential consequences on cardiovascular events, such as arrhythmias, heart failure, myocardial infarction and death. Lastly, we briefly review additional GLP-1R agonists in clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据